

ORIGINAL RESEARCH

Mucoactive agents for acute respiratory failure in the critically ill: a systematic review and meta-analysis

Rohan Anand ⁽ⁱ⁾, ¹ Daniel F McAuley, ¹ Bronagh Blackwood, ¹ Chee Yap, ¹ Brenda ONeill, ² Bronwen Connolly, ^{1,3,4} Mark Borthwick, ⁵ Murali Shyamsundar, ¹ John Warburton, ⁶ David van Meenen, ⁷ Frederique Paulus, ⁷ Marcus J Schultz, ^{7,8,9} Paul Dark, ¹⁰ Judy M Bradley¹

ABSTRACT

► Additional material is published online only. To view please visit the journal online (http://dx.doi.org/10.1136/ thoraxjnl-2019-214355).

For numbered affiliations see end of article.

Correspondence to

Rohan Anand, Queen's University Belfast Wellcome-Wolfson Institute for Experimental Medicine, Belfast BT9 7BL, UK; ranand01@qub.ac.uk

Received 19 November 2019 Revised 8 April 2020 Accepted 21 April 2020 Published Online First 8 June 2020 **Purpose** Acute respiratory failure (ARF) is a common cause of admission to intensive care units (ICUs). Mucoactive agents are medications that promote mucus clearance and are frequently administered in patients with ARF, despite a lack of evidence to underpin clinical decision making. The aim of this systematic review was to determine if the use of mucoactive agents in patients with ARF improves clinical outcomes.

Methods We searched electronic and grey literature (January 2020). Two reviewers independently screened, selected, extracted data and quality assessed studies. We included trials of adults receiving ventilatory support for ARF and involving at least one mucoactive agent compared with placebo or standard care. Outcomes included duration of mechanical ventilation. Meta-analysis was undertaken using random-effects modelling and certainty of the evidence was assessed using Grades of Recommendation, Assessment, Development and Evaluation.

Results Thirteen randomised controlled trials were included (1712 patients), investigating four different mucoactive agents. Mucoactive agents showed no effect on duration of mechanical ventilation (seven trials, mean difference (MD) -1.34, 95% CI -2.97 to 0.29, $I^2=82\%$, very low certainty) or mortality, hospital stay and ventilator-free days. There was an effect on reducing ICU length of stay in the mucoactive agent groups (10 trials, MD -3.22, 95% CI -5.49 to -0.96, $I^2=89\%$, very low certainty).

Conclusion Our findings do not support the use of mucoactive agents in critically ill patients with ARF. The existing evidence is of low quality. High-quality randomised controlled trials are needed to determine the role of specific mucoactive agents in critically ill patients with ARF.

PROSPERO registration number CRD42018095408.

Check for updates

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Anand R, McAuley DF, Blackwood B, *et al. Thorax* 2020;**75**:623–631.

BMJ

INTRODUCTION

Acute respiratory failure (ARF) is a common cause of admission into intensive care units (ICUs) and is associated with high acute and late mortality rates.^{1–3} The mainstay of respiratory supportive therapy is invasive and non-invasive mechanical ventilation.⁴ A considerable proportion of patients within ICU are mechanically ventilated, with audit data from the USA suggesting up to 40% of patients may be receiving mechanical ventilation at any

Key messages

What is the key question?

Do mucoactive agents improve clinically important outcomes in critically ill, ventilated patients with acute respiratory failure?

What is the bottom line?

This systematic review found limited trials and evidence that mucoactives improved clinically important outcomes in patients ventilated with acute respiratory failure.

Why read on?

 We describe four mucoactive agents across 13 trials and explain why we urge mucoactive use with caution in this population.

given time. In the UK, an estimated 116 000 adult ICU admissions alone are for respiratory support per annum.⁵

Patients mechanically ventilated in the ICU for ARF can experience mucus accumulation due to several reasons including infection, muscle weakness, mucociliary escalator dysfunction and suppression of cough reflex due to analgesia and sedation used to facilitate ventilation.⁶ Targeted respiratory physiotherapy treatments, including mucoactive agents, are used to manage secretion retention.⁷⁸ Mucoactive agents are a class of medications that aid the removal of mucus from the lung and are generally subclassified according to their mechanism of action.⁹ Mucolytics, such as N-acetylcysteine (NAC), work by breaking mucin crosslinking, mucoregulators such as carbocisteine decrease mucus production, expectorants such as hypertonic saline (HTS) work by increasing water content, and mucokinetics such as ambroxol work by increasing pulmonary mucus transport by acting on the cilia. This classification is not strict as it is known that some mucoactive agents, such as HTS, have multiple mechanisms of action.¹⁰ They can be delivered to patients either via inhalation direct to the lungs or systemically; oral or intravenous.

There are no systematic reviews on the use of mucoactive agents in mechanically ventilated or high-flow nasal oxygen (HFNO) populations specific to ARF. Furthermore, the National Institute for Health and Care Excellence,¹¹ the British Thoracic Society¹²





Figure 1 PRISMA flow diagram. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.

and the Intensive Care Society^{12 13} do not provide published recommendations regarding mucoactive agent use in this population. In contrast to the lack of evidence of efficacy, surveys show mucoactive agent usage is common^{14–16} with a recent survey of ICU-level practice finding mucoactive agents were used in 83% of ICU in the UK, although with notable variation in prescribing practices.¹⁷ This survey indicated high use of NAC, HTS and carbocisteine, with the most highly ranked indication for use being thick secretions, and the most widely expected benefit that of reduced duration of mechanical ventilation. Practice relating to the use of mucoactive agents is currently guided by anecdotal evidence, local experience and clinician preference.

Objective

To systematically review the current evidence for the use of mucoactive agents in critically ill patients with ARF, with the objective of determining improvement on clinically important outcomes.

METHODS

Deviations between this review and protocol are listed in the online supplementary material.

Types of studies

We included any design of clinical trial that compared at least one mucoactive agent with standard care or placebo in ventilated patients (including HFNO) with ARF. We excluded observational, case series, pilot/feasibility and longitudinal studies.

Types of participants

We included trials that studied adults (at least 15 years old) who were mechanically ventilated, either invasively, non-invasively or had received HFNO for treatment of ARF. Invasive mechanical ventilation was defined as a participant requiring an artificial tracheal airway. Non-invasive ventilation was defined as application of respiratory support via a sealed face-mask, nasal mask, mouthpiece, or full face visor or helmet, without the need for tracheal intubation. HFNO was defined as any cannula sitting within the nostrils and delivering heated and humidified oxygen with a gas flow rate of ≥ 20 L/min.¹⁸ ARF was defined to include the following conditions: acute hypoxic respiratory failure (type 1), acute hypercapnic respiratory failure (type 2), acute respiratory distress syndrome (ARDS) and acute lung injury (ALI). Patients could present with one or more of these conditions. Patients with pre-existing chronic respiratory conditions with sputum abnormalities such as bronchiectasis or cystic fibrosis were excluded, however, patients with other chronic respiratory conditions including chronic obstructive pulmonary disease (COPD) were included.

Types of interventions

We included trials involving at least one mucoactive agent. A mucoactive agent was defined as any agent used to assist the removal of mucus/sputum from the lungs.^{9 19} We included any method of delivery as mucoactive mechanisms of action impact on the same clinical outcomes.²⁰ We did not regard isotonic

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants	Blinding of personnel	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Bandeshe 2016 (heparin neb)	•	•	•	•	•	•	•	•
Bernard 1997 (NAC IV)	•	?	•	•	?	•	•	?
Dixon 2010 (heparin neb)	•	•	•	•	?	•	•	•
Domenighetti 1997 (NAC IV)	?	?	•	•	?	•	•	?
Jepsen 1992 (NAC IV)	?	?	•	•	?	•	•	?
Masoompour 2015 (NAC neb)	•	•	•	•	?	•	•	•
Moradi 2009 (NAC IV)	?	?	?	?	?	•	•	•
Ortolani 2000 (NAC IV)	?	?	•	•	•	•	•	?
Saleh 2017 (heparin neb)	?	?	?	?	?	•	•	•
Suter 1994 (NAC IV)	?	?	•	•	?	•	•	?
Van Meenen 2018 (NAC neb)	•	•	•	•		•	•	•
Yongjun 2014 (ambroxol IV)	?	?	?	?	?	•	•	•
Zaytoun 2017 (HTS neb)			?	?	?	•	?	•

Figure 2 Risk of bias for included trials. (van Meenen 2018 had stated in their protocol that an economic analysis would be performed. This however was not within the trial publication. Following correspondence with authors this was a shared decision by them and the editor of JAMA. This cost related data is currently being used to prepare a separate publication to be submitted aside of the main clinical results. therefore, we assessed rob for selective outcome reporting as low.) HTS, hypertonic saline; NAC, N-acetylcysteine.

Table 1 Characteristics of included studies											
Author and year	No of participants	Age (years, mean±SD)	Population (ventilation as described in paper)	Mucoactive agent intervention and dose	Control	Duration to last follow-up (days)	Outcomes measured relevant for this r eview				
Bandeshe ³⁸ 2016*	214	Placebo: 59 Usual care: 62 Intervention: 57 (reported as medians)	Mixed (invasive mechanical ventilation)	Heparin (Nebulised; 2 mL 5000 units every 6 hours)	Placebo (0.9%) NaCl Usual care	Not reported	Mortality, ICU stay, hospital stay, duration of mechanical ventilation and adverse events.				
Bernard ³³ 1997	46	Control: 47±4 Intervention: 43±6	ARDS (mechanically ventilated)	NAC (Intravenous; 70 mg/kg, every 8 hours, for 10 days)	Placebo (5% dextrose in water)	30	Mortality, ventilator free days at day 30 and adverse events.				
Dixon ⁴⁰ 2010	50	Control: 55.5±17.0 Intervention: 56.0±16.5	Mixed (invasive mechanical ventilation)	Heparin (Nebulised; 25 000 U/5 mL every 4 or 6 hours)	Placebo (0.9% NaCl)	60	Mortality, ventilator free days at day 28, ICU stay, hospital stay and adverse events.				
Domenighetti ³¹ 1997	42	Control: 52.4±17 Intervention: 52.1±17.8	ARDS (invasive and non-invasive ventilation)	N-acetylcysteine (Intravenous; 190 mg/kg/ day, for 2 days)	Placebo (not defined in paper)	ICU discharge (not reported)	Mortality, ICU stay, duration of ventilation and adverse events.				
Jepsen ³⁵ 1992	66	Control: 51.5 Intervention: 50.5	ARDS (tracheal intubation)	N-acetylcysteine (Intravenous; 150 mg/kg then 20 mg/kg/hour for 6 days)	Placebo (not defined in paper)	60	Mortality.				
Masoompour ³⁰ 2015	40	Control: 50.6±21 Intervention: 59.7±22	Mixed (invasive ventilation)	N-acetylcysteine (Nebulised; 2 mL of 20%, 3 times per day)	Control (isotonic saline)	1	Mortality.				
Moradi ³⁷ 2009	27	Control: 49.2±4.5 Intervention: 48.4±5.5	ARDS/ALI (mechanically ventilated)	N-acetylcysteine Intravenous; 150 mg/kg diluted in 5% dextrose day 1 then 50 mg/kg/day for 3 consecutive days)	Placebo (5% dextrose)	Not reported	Mortality, ICU stay and duration of mechanical ventilation.				
Ortolani ³⁶ 2000	36	Control: 55±13 Intervention: 57±14	ARDS (artificial ventilation)	N-acetylcysteine (Intravenous; 50 mg/kg in 5% dextrose, every 8 hours for 9 days)	Placebo (5% dextrose in water)	30	Mortality and ICU stay.				
Saleh ³⁹ 2017	80	Control: 34.8±14.8 Intervention: 34.3±14.6	ARDS (mechanical ventilation)	Heparin (Nebulised; 5000 IU heparin mixed with 3 mL of normal Saline every 4 hours)	Standard Care (Conventional management of ARDS: Mechanical ventilation with open lung protective strategy, conservative fluid management, solumedrol at a dose of 1 mg/kg/day, antimicrobials and bronchodilators if needed)	End of ICU stay	Mortality, ICU stay and duration of mechanical ventilation.				
Suter ³² 1994	61	Control: 48.1±21.9 Intervention: 46.6±19.7	ALI (invasive ventilation)	N-acetylcysteine (Intravenous; 40 mg/kg/day for 3 days)	Placebo (not defined in paper)	ICU discharge (not reported)	Mortality, ICU stay and adverse effects.				
Van Meenen ²⁶ (NEBULAE) 2018†	922	Control: 66 Intervention: 65 (median values reported)	Mixed (invasive)	On demand N- acetylcysteine (Nebulised; 300 mg with 2.5 mg salbutamol)	Routine N- acetylcysteine (300 mg with 2.5 mg salbutamol, 4 times daily for upto 28 days)	90	Mortality, duration of ventilation, ventilator free days at day 28, ICU stay, hospital length of stay and adverse events.				
Yong-Jun ³⁴ 2014	68	Control: 57±8 Intervention: 58±12	ARDS (invasive and non-invasive ventilation)	Ambroxol (Intravenous; 1005 mg/day, for 7 days)	Placebo (0.9% isotonic saline)	Not reported	Duration of ventilation, ICU stay and hospital stay.				
Dahruog 2017 ²⁹	60	Control: 41.87±16.44 intervention: 41.30±14.13	ARDS (invasive ventilation)	Hypertonic saline (nebulised; 3%, 4 mL once daily, for 7 days)	Control (not defined in paper)	30	Mortality, duration of mechanical ventilation, ICU stay and adverse events.				

*Standard care and placebo were combined as one group using methodology from the Cochrane Handbook Table 7.7, as this was a three arm trial comparing placebo, mucoactive and standard care.

tThe control group (routine nebulisation) was regarded as mucoactive group in the analyses and the on-demand group was regarded as the control/standard care. The analyses compared the routine nebulisation group to a subset of patients from the on-demand group that received no nebulisations (n=268). This excluded patients that received NAC and salbutamol treatment in the control group.

ALI, acute lung injury; ARDS, acute respiratory distress syndrome; ICU, intensive care unit; NAC, N-acetylcysteine.

saline as an active mucoactive agent as it was used as the placebo/ control group in several trials.

Outcomes

The primary outcome for invasive/non-invasive ventilated patients was duration of ventilation and for HFNO patients was intubation rate. Secondary outcomes were time to extubation, reintubation, number of ventilator free days at day 28, duration of ICU stay, duration of hospital stay, mortality (all cause within 28, 60 and 90 days), health-related quality of life, adverse events/development of other pathologies and healthcare related costs. All outcomes included were from a recently published core outcome set for trials of interventions intending to modify the duration of mechanical ventilation.²¹

Search strategy

We searched three electronic databases (MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials), three clinical

	Favours	[mucoactives]		Placebo/	Standard Car	re		Mean Difference	Mean Dif	ference
Study or Subgroup	Mean [Days]	SD [Days]	Total	Mean [Days]	SD [Days]	Total	Weight	IV, Random, 95% CI [Days]	IV, Random, 9	95% CI [Days]
1.3.2 Ambroxol IV										
Yongjun 2014 (ambroxol IV)	6.9	2.5	35	8.9	2.7	33	19.5%	-2.00 [-3.24, -0.76]	-	
Subtotal (95% CI)			35			33	19.5%	-2.00 [-3.24, -0.76]	•	
Heterogeneity: Not applicable										
Test for overall effect: Z = 3.16 (P =	= 0.002)									
1.3.3 Heparin neb										
Bandeshe 2016 (heparin neb)	6.3	6.5	71	5.8	5.8	143	17.4%	0.50 [-1.29, 2.29]	-	
Saleh 2017 (heparin neb)	9.6	13.5	40	13.5	3.1	40	8.7%	-3.90 [-8.19, 0.39]		
Subtotal (95% CI)			111			185	20.1%	-1.25 [-5.47, 2.97]		
Heterogeneity: Tau= 6.87; Chi=	3.44, df = 1 (H	r = 0.06); I* = 7	1%							
Test for overall effect: Z = 0.58 (P =	= 0.56)									
134 HTS neb										
Zerteun 2017 (LTC nob)	0.6	2.4	20	11.0	2.2	20	10.00	2 20 (2 27 1 02)		
Subtotal (95% CI)	9.0	2.4	30	11.0	2.2	30	19.8%	-2.20 [-3.37, -1.03]	•	
Heterogeneity Not applicable							1010/1	2120[0101] 1100]	•	
Tect for overall effect: 7 = 3.70 (P -	- 0.0002)									
	- 0.0002/									
1.3.5 NAC IV										
Domenighetti 1997 (NAC IV)	8.1	6.5	22	9.3	6.6	20	9.5%	-1.20 [-5.17, 2.77]		
Moradi 2009 (NAC IV)	24.8	8.5	14	32.9	9.8	13	4.4%	-8.10 [-15.04, -1.16]		
Subtotal (95% CI)			36			33	13.9%	-4.04 [-10.69, 2.62]		
Heterogeneity: Tau ² = 15.48; Chi ²	= 2.86, df = 1 ($(P = 0.09); I^2 = I$	65%							
Test for overall effect: Z = 1.19 (P =	= 0.23)									
1.3.6 NAC neb										
Van Meenen 2018 (NAC neb)	5.3	6	467	4.3	5.8	268	20.7%	1.00 [0.12, 1.88]		t
Subtotal (95% CI)			467			268	20.7%	1.00 [0.12, 1.88]		•
Heterogeneity: Not applicable										
Test for overall effect: Z = 2.22 (P =	= 0.03)									
T-1-1/054/ 01			070			6.47	400.00	4 2 4 7 2 2 7 2 2 2 2		
Total (95% CI)			6/9			547	100.0%	-1.34 [-2.97, 0.29]	-	
Heterogeneity: Tau* = 3.13; Chi* =	33.08, df = 6 ((P < 0.0001); l²	= 82%						-20 -10 0) 10 20
Test for overall effect: Z = 1.62 (P =	= 0.11)	1 /D = 0.0004	17 - 04						Favours [mucoactives]	Favours [control]
I HELING SUGMERTING ALBORATION COS. I. N	u = - (D M (OI) =	. A IP S		1 TO 184						

Figure 3 Duration of ventilation. Forest plot of comparison: mucoactive agent versus placebo/standard care. HTS, hypertonic saline; IV, intravenous; NAC, N-acetylcysteine; Neb, nebuliser.

trial registries (EU Clinical Trial Register, ClinicalTrials.gov, WHO trial registry) and grey literature (OpenGrey). With the aid of a medical librarian, a comprehensive search strategy was developed using appropriate Medical Subject Headings (MeSH) and keywords (online supplementary material). The references of relevant articles were also checked for potentially eligible trials. All searches were from database inception to 9 January 2020. The search was for English language only articles.

Data collection and analysis

Search results were imported into a systematic review manager (Covidence: www.covidence.org) for screening and data extraction.

Selection of studies

Two review authors (RA and CY) independently screened titles and abstracts from the searches for inclusion. The full text of publications was retrieved for potentially eligible studies. Fulltext publications were additionally also independently screened for inclusion by a third review author (DM) to confirm inclusion. Any disagreements or uncertainties were resolved through discussion or with consultation of the other review authors.

Data extraction

Data from included trials were extracted independently by two review authors (RA and CY) including: the type and setting of the study, number of participants, eligibility criteria (online supplementary material), nature of the intervention(s) in each group (dose and route of administration of mucoactive agent), time points of outcome measurement and results of outcomes. Any disagreements were resolved through discussion or with consultation of the other review authors. Study authors were contacted to request data that were not reported or insufficient in the main publication.

Assessment of risk of bias

Two review authors (RA and CY) independently used the Cochrane Risk of Bias tool for randomised trials within Covidence.²² Risk

of bias was assessed across eight domains: sequence generation, allocation concealment, blinding of outcome assessors, blinding of participants, blinding of personnel, selective outcome reporting, incomplete outcome data and other sources of bias. Each potential source of bias was marked as high, low or unclear.

Measures of effect

The unit of analysis was the participant. Binary variables were calculated as odds ratios (ORs) with 95% confidence intervals (CIs). Continuous variables were calculated as mean differences (MDs) with 95% CIs. When analysing for mortality, we used the longest fully reported follow-up.²³ Meta-analyses were performed using Review Manager V.5.3 and statistical heterogeneity evaluated using the I² statistic, with a value of >50% implying substantial heterogeneity.²⁴ Trials with standard care or a placebo as a comparator were grouped as 'non-mucoactive agent' and synthesised together. This was then compared with the pooled mucoactive group. We estimated mean values from trials that reported any relevant median values using methodologies from Wan *et al.*²⁵ Analysis was undertaken using random methods models.

For the NEBULAE trial (Effect of On-Demand vs Routine Nebulization of Acetylcysteine With Salbutamol on Ventilator-Free Days in Intensive Care Unit Patients Receiving Invasive Ventilation),²⁶ the control group (routine nebulisation of a mucoactive agent) was regarded as the mucoactive agent group in the analyses and the 'on-demand' group was regarded as the control/ standard care. The analyses compared the routine nebulisation group, that is, the intervention group to a subset of patients from the on-demand group that received no nebulisations, that is, the control group (n=268). This excluded patients that received NAC and salbutamol treatment in the control group. In the original trial, the control group was the routine nebulisation group, and the intervention group was the on-demand group.

Subgroup analysis

Where possible we performed meta-analysis based on specific mucoactive agent when there was adequate data. This included

	Favours [experin	nentall	Control			Odds Ratio	Odds Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI			
1.2.2 Heparin neb										
Bandeshe 2016 (heparin neb)	10	71	26	143	12.2%	0.74 [0.33, 1.63]				
Dixon 2010 (heparin neb)	7	25	5	25	6.0%	1.56 [0.42, 5.78]	-			
Saleh 2017 (heparin neb)	8	40	9	40	8.2%	0.86 [0.29, 2.52]				
Subtotal (95% CI)		136		208	26.3%	0.89 [0.50, 1.58]	-			
Total events	25		40							
Heterogeneity: Tau ² = 0.00; Chi ² = 0.91, df = 2 (P = 0.63); I ² = 0%										
Test for overall effect: Z = 0.40 (P	= 0.69)									
1.2.3 HTS neb										
Zavtoun 2017 (HTS neh)	8	30	21	30	7.6%	0.16/0.05/0.481				
Subtotal (95% CI)	Ŭ	30	21	30	7.6%	0.16 [0.05, 0.48]				
Total events	8		21							
Heterogeneity: Not applicable	•									
Test for overall effect: Z = 3.24 (P	= 0.001)									
1.2.4 NAC IV										
Bernard 1997 (NAC IV)	5	14	6	15	4.8%	0.83 [0.19, 3.75]				
Domenighetti 1997 (NAC IV)	7	22	5	20	5.7%	1.40 [0.36, 5.41]				
Jepsen 1992 (NAC IV)	17	32	17	34	9.5%	1.13 [0.43, 2.98]				
Moradi 2009 (NAC IV)	5	14	10	13	3.9%	0.17 [0.03, 0.90]	-			
Ortolani 2000 (NAC IV)	5	12	7	12	4.2%	0.51 [0.10, 2.59]				
Suter 1994 (NAC IV)	7	32	10	29	7.5%	0.53 [0.17, 1.66]				
Subtotal (95% CI)		126		123	35.6%	0.72 [0.42, 1.24]				
Total events	46		55							
Heterogeneity: Tau* = 0.01; Chi*	= 5.13, df = 5 (P = 0	.40); 1* = :	3%							
Test for overall effect: $Z = 1.17$ (P	= 0.24)									
1.2.5 NAC neb										
Masoompour 2015 (NAC neb)	10	20	7	20	6.3%	1.86 [0.52, 6.61]				
Van Meenen 2018 (NAC neb)	149	467	95	268	24.1%	0.85 [0.62, 1.17]				
Subtotal (95% CI)		487		288	30.4%	0.98 [0.55, 1.74]	•			
Total events	159		102							
Heterogeneity: Tau ² = 0.08; Chi ² = 1.36, df = 1 (P = 0.24); I ² = 26%										
Test for overall effect: Z = 0.08 (P	= 0.94)									
Total (95% CI)		779		649	100.0%	0.75 [0.52, 1.08]	•			
Total events	238		218							
Heterogeneity: Tau ² = 0 11: Chi ² = 16 28 df = 11 (P = 0 13): I ² = 32%										
Test for overall effect: Z = 1.56 (P	= 0.12)						U.U1 U.1 1 10 100			
Test for subgroup differences: C	hi ² = 8.66, df = 3 (P	= 0.03), P	² = 65.3%				Favours (experimental) Favours (control)			

Figure 4 Mortality. Forest plot of comparison: mucoactive agent versus placebo/standard care. HTS, hypertonic saline; IV, intravenous; M-H, Mantel-Haenszel; NAC, N-acetylcysteine; Neb, nebuliser.

a subgroup analysis of mucoactive agent type for duration of ventilation, mortality and duration of ICU stay. There were insufficient trials to test subgroup differences in other outcomes.

Sensitivity analysis

Sensitivity analyses were not undertaken due to the small number of trials and a lack of aggregate data.²⁷

Quality of evidence

Five authors (RA, JB, BB, BC and BO) determined an overall certainty of the evidence for the outcomes using the principles of the GRADE system (Grades of Recommendation, Assessment, Development and Evaluation) to rate the strength of findings into one of four levels: high, moderate, low or very low.²⁸ We generated a 'Summary of Findings' table using GRADEpro software (www.gradepro.org) to present outcome-specific information regarding overall certainty of evidence from studies. Certainty of evidence was assessed according to study design, risk of bias, inconsistency, indirectness, imprecision, publication bias and any other factors, for example, confounding and downgraded by one (for serious) or two (for very serious) levels as necessary.

RESULTS

Literature search

The search identified 557 results (figure 1). After importing into covidence, five duplicates were identified and removed. After title and abstract screening, 510 records were excluded leaving 42 records for full text screening. After full-text screening, 13 completed trials were eligible for inclusion in the review^{26 29-40} with two trials identified as ongoing.⁴¹⁴² A list of the 27 excluded studies, with reasons for exclusion, are within the online

supplementary material. Also included within the online supplementary material are the numbers of search results found from each data resource.

Study characteristics and risk of bias

Characteristics of included trials are summarised in table 1. All studies were prospective randomised parallel group controlled trials, totalling 1712 patients. Mucoactive agents investigated included NAC (n=8 trials), heparin (n=3 trials), ambroxol (n=1 trial) and HTS (n=1). Nine trials included patients with ALI or ARDS, and four trials with a mixed ARF population. The number of participants in the trials ranged from 27 to 922. The longest follow-up was reported at 90 days. No trials involved patients receiving HFNO.

Risk of bias assessment is described in figure 2. Six trials²⁶ ²⁹ ³⁰ ³³ ³⁶ ⁴⁰ were judged as high risk of bias in at least one domain, six trials³¹ ³² ³⁴ ³⁵ ³⁷ ³⁹ were deemed as an unclear risk of bias across at least three domains and one trial³⁶ overall had a low risk of bias. Ten trials^{29–37} ³⁹ had high or unclear risk of bias due to allocation concealment and nine^{29–32} ^{34–37} ³⁹ due to sequence generation. Twelve²⁶ ^{29–37} ³⁹ ⁴⁰ trials had high or an unclear risk of bias due to blinding. All trials were at a low risk of attrition bias. One trial³³ was at high risk of reporting bias.

Duration of mechanical ventilation

The duration of mechanical ventilation was reported in seven trials²⁶ ²⁹ ³¹ ³⁴ ³⁷⁻³⁹ (n=1226 patients). Pooled analysis showed no effect with the use of mucoactive agents with high heterogeneity (MD -1.34, 95% CI -2.97 o 0.29, p=0.11, 1^2 =82%) (figure 3). There was no noticeable publication bias with funnel plot estimates (online supplementary material).

	Muc	oactiv	е	Placebo/Standard Care		Care	Mean Difference		Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI	
1.4.2 Ambroxol IV										
Yongjun 2014 (ambroxol IV) Subtotal (95% CI)	10.2	2.7	35 35	14.6	3.2	33 33	12.9% 12.9%	-4.40 [-5.81, -2.99] -4.40 [-5.81, -2.99]	→	
Heterogeneity: Not applicable Test for overall effect: Z = 6.11 (F	P < 0.000	01)								
1 4 3 Henarin neh										
Pandacha 2016 (banarin nah)	0	7	72	0 1	6.0	142	12.2%	0 10 1 2 07 1 971		
Divon 2010 (honorin noh)	0.4	7 4	25	1.4	12.1	26	7 1 06	4 60 1 10 60 1 201		
Calob 2017 (hoparin nob)	127	1.4	20	177	2.7	20	12.6%	-4.00 [-10.30, 1.30] 6.00 [6.76 2.34]		
Subtotal (95% CI)	12.7	4.5	137	17.7	5.7	208	31 0%	-3.01 [-6.01 0.88]		
Hotorogeneity Teuz - 0.17: Chiz	- 12 54	46 - 0	/D = 0.0	041:12-05	ov.	200	51.570	-5.01 [-0.51, 0.00]		
Test for overall effect: Z = 1.52 (P	= 13.54, P = 0.13	ui = 2	(= 0.0	101), 1-= 65	70					
	,									
1.4.4 HTS neb										
Zaytoun 2017 (HTS neb) Subtotal (95% CI)	13.1	2.7	30 30	16.7	4.1	30 30	12.5% 12.5%	-3.60 [-5.36, -1.84] -3.60 [-5.36, -1.84]	—	
Heterogeneity: Not applicable									•	
Test for overall effect: Z = 4.02 (P	<pre>< 0.000</pre>	1)								
		.,								
1.4.5 NAC neb										
Van Meenen 2018 (NAC neb)	6.7	8.2	467	5.2	5.4	268	13.2%	1.50 [0.51, 2.49]		
Subtotal (95% CI)			467			268	13.2%	1.50 [0.51, 2.49]	◆	
Heterogeneity: Not applicable										
Test for overall effect: Z = 2.98 (P	P = 0.003)								
1 A 6 NAC IV										
Demoniahotti 1007 /blac ba	12.0	7.0	22	10.5	0.6	20	0.40	4 70 / 0 50 0 4 01		
Maradi 2000 (NAC IV)	13.0	7.0	22	10.0	0.0	20	0.470	-4.70[-9.52, 0.12]		
Ortologi 2009 (NAC IV)	32.8	7.0	14	42.1	10.5	10	6.00%	-9.20 [-10.07, -2.33]		
Cutor 1004 (NAC IV)	11.0	10.5	12	12.2	06	12	0.970	-0.00[-12.01, 0.01]		
Subtotal (95% CI)	11.5	10.5	32	12.2	9.0	29	20.5%	-0.90 [-5.94, 4.14]		
Hotorogonoity Tou2 - 2 71: Chi2	- 4 00 4	K- 2/	00	1.12 - 250		14	23.370	-4.70 [-7.52, -1.40]		
Heterogeneiny, Faur = 2, 71, Chr = 4, 00, 01 = 3 (F = 0.20), F = 25% Test for overall effect. Z = 2.86 (P = 0.004)										
Total (95% CI)			749			613	100.0%	-3.22 [-5.49, -0.96]	•	
Heterogeneity Tau ² = 9.86: Chi ²	= 84 11	df = 9	(P < 0.0	0001): 12 =	89%					
Test for overall effect: 7 = 2.79 /P	2 = 0.005)	0.0						-20 -10 0 10 20	
Test for subgroup differences: C	hi ² = 61	, 12 df=	= 4 (P <	0.00001	² = 93.5%				Favours [mucoactive] Favours [control]	
rearial adaptions dimensioned. On POTA2, dr P 41 - 0.00001,1 - 00.000										



Mortality

Mortality was reported in 12 trials^{26 29-33 35-40} (n=1428 patients). Mucoactive agents had no effect on mortality (OR 0.75, 95% CI 0.52 to 1.08, p=0.12, I²=32%). Subgroup analysis showed no difference in reduction of mortality with use of NAC intravenous (OR 0.72, 95% CI 0.42 to 1.24, p=0.24, I²=3%), NAC neb (OR 0.98, 95% CI 0.55 to 1.74, p=0.94, I²=26%) or heparin (OR 0.89, 95% CI 0.50 to 1.58, p=0.69, I²=0%) all with low heterogeneity (figure 4). There was no noticeable publication bias with funnel plot estimates (online supplementary material).

Duration of ICU stay

Duration of ICU stay was reported in 10 trials²⁶ ²⁹ ³¹ ³² ³⁴ ³⁶⁻⁴⁰ (n=1362 patients). There was a difference in duration of ICU stay favouring the use of mucoactive agents with high heterogeneity (overall MD -3.22, 95% CI -5.49 to 0.96, p=0.005, I²=89%). Subgroup analysis showed a difference in reduction of ICU stay with NAC intravenous with low heterogeneity (overall MD -4.70, 95% CI -7.92 to -1.48, p=0.004, I²=25%) and no difference in ICU stay with the use of nebulised heparin (overall MD -3.01, 95% CI -6.91 to 0.88, p=0.13, I²=85%) (figure 5). There was slight publication bias with funnel plot estimates (online supplementary material).

Duration of hospital stay

The duration of hospital stay was reported in four trials^{26 34 38 40} (1067=patients). Pooled analysis showed no difference with the use of mucoactive agents with high heterogeneity (overall MD -2.05, 95% CI -5.87 to 1.76, p=0.29, I²=81%) (figure 6).

Ventilator free days

Three trials reported ventilator-free days, two at day 28^{26} ⁴⁰ and one trial reported at day $30.^{33}$ Pooled analysis showed no difference in the number of ventilator free days at day 28 with high heterogeneity (overall MD 2.35, 95% CI –1.76 to 6.45, p=0.26, I²=77%) (figure 7). For one study,³³ the median number of ventilator free days was 11 for the mucoactive agent group and three for the placebo group. This study could not be incorporated into the meta-analysis as the mean (SD) could not be estimated.

Intubation rate, time to extubation, reintubation, healthrelated quality of life and healthcare-related costs

No trials reported outcomes for intubation rate, time to extubation, reintubation, health-related quality of life or healthcarerelated costs.



Figure 6 Duration of hospital stay. Forest plot of comparison: mucoactive agent versus placebo/standard care. IV, intravenous; NAC, N-acetylcysteine; Neb, nebuliser.



Figure 7 Ventilator free days at day 28. Forest plot of comparison: mucoactive agent versus placebo/standard care. IV, intravenous; NAC, N-acetylcysteine; Neb, nebuliser.

Adverse events and development of other pathologies

Three trials, ²⁶ ³³ ³⁸ investigating nebulised NAC, intravenous NAC and nebulised Heparin, respectively, reported on adverse events in both arms. Four further trials reported the number of adverse events only in the mucoactive agent arm of the study. Two trials analysed differences between groups. The NEBULAE trial²⁶ reported that the proportion of patients developing one or more nebulisation-related adverse events was significantly higher in the mucoactive group that received nebulised NAC (p < 0.001), however, the development of other pathologies/pulmonary complications were not significantly different between the two groups. One trial,²⁹ investigating nebulised HTS, reported a significantly higher development of ventilator associated pneumonia in the control group, but did not report the original number of events in each arm (p=0.014). One trial⁴⁰ investigating nebulised heparin reported no differences in number of days that patients had blood stained sputum. Further details on adverse events are summarised in the online supplementary material.

Summary of findings

Certainty of evidence is summarised in table 2. Downgrading of certainty levels was primarily related to high risk of bias and imprecision (high heterogeneity).

DISCUSSION

This systematic review found that use of mucoactive agents did not improve outcomes including duration of ventilation,

mortality, duration of hospital stay or ventilator-free days at day 28, although they did decrease ICU stay. The GRADE evaluation showed that the certainty level of evidence for four outcomes in the review was very low, with only mortality having a moderate level of certainty of evidence. Certainty of the evidence was primarily impacted by a risk of bias mostly related to random sequence generation and allocation concealment. We note there are differences in our risk of bias assessment in some trials that were also included in a previous review, these are explained in the online supplementary material. Other reasons affecting the evidence included small sample size, mixed patient populations and high heterogeneity. Our findings indicate that further evidence is required to determine the effectiveness of mucoactive agents for critically ill patients with ARF. Future trials should be designed to address the methodological limitations identified in studies included in this review. Our systematic review echoes a previous expert narrative review in 2017 which concluded use of mucoactive agents within the critically ill is in need of evidencebased recommendations.¹⁹

Two mucoactive agents that are used within critical care units, recombinant human DNase (also known as RhDNase) and carbocisteine were not investigated in trials in this review, therefore, highlighting the lack of evidence to support their use in ventilated patients with ARF. This mirrors findings from a review of aerosolised mucoactive agents in hospitalised patients⁴³ and guidelines by The American Association for Respiratory Care,⁴⁴ although these publications were not targeted at critically

Table 2 GADE and summary of findings										
Summary of findings: mucoactive agents compared with non-mucoactive agents for acute respiratory failure										
Patient or population: ventilated with acute respiratory failure Setting: intensive care unit (ICU) Intervention: mucoactive agents Comparison: non-mucoactive agents										
	No of participants	Certainty of the	Deleting offerst	Anticipated absolute effects						
Outcomes	(studies) Follow-up	(GRADE)	(95% CI)	Risk with non-mucoactives	Risk difference with mucoactives					
Duration of ventilation	1226 (7 RCTs)	⊕○○○ VERY LOW*	-	The mean duration of Ventilation was 0	MD 1.34 lower (2.97 lower to 0.29 higher)					
Mortality	1428 (12 RCTs)	⊕⊕⊕⊖ MODERATE†	OR 0.75 (0.52 to 1.08)	336 per 1000	61 fewer per 1000 (128 fewer to 17 more)					
Duration of ICU stay	1362 (10 RCTs)	⊕○○○ VERY LOW‡	-	The mean duration of ICU stay was 0	MD 3.22 lower (5.49 lower to 0.96 lower)					
Duration of hospital stay	1067 (4 RCTs)	⊕○○○ VERY LOW§	-	The mean duration of Hospital stay was 0	MD 2.05 lower (5.87 lower to 1.76 higher)					
Ventilator free days at day 28 785 $\oplus \bigcirc \bigcirc \bigcirc$ - The mean ventilator-free days at day 28 was 0 MD 2.35 higher (1.76 lower to 6.45 higher)										
GRADE working group grades of evidence: High certainty: We are very confident that the true effect lies close to that of the estimate of the effect. Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect. Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of the effect. Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of the effect. Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of the effect. The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). ************************************										

Fisks of bias was deemed serious as the majority of trials (9/10) had an unclear or high risk of bias in at least one domain. Inconsistency was deemed as very serious due to high neterogeneity (1 = 2 %).
Fisks of bias was deemed serious as the majority of trials (9/10) had an unclear or high risk of bias in at least one domain.

§Risk of bias was deemed serious as the majority of trials (3/4) had an unclear or high risk of bias in at least one domain. Inconsistency was deemed as very serious due to high heterogeneity (l²=81%). ¶Risk of bias was deemed serious as both trials (2/2) had an unclear or high risk of bias in at least one domain. Inconsistency was deemed as very serious due to high heterogeneity (l²=77%). GRADE, Grades of Recommendation, Assessment, Development and Evaluation; MD,mean difference. ill patients in the ICU. There is evidence of effect with these mucoactive agents in other respiratory conditions. Carbocisteine shows benefit for patients with COPD⁴⁵ and RhDNase for cystic fibrosis.⁴⁶ However, it should not be assumed that a mucoactive agent demonstrated to be effective in one clinical population will necessarily be effective in another population and indeed there may be potential for harm. For example, although there is evidence to support RhDNase in cystic fibrosis, a well-designed and powered clinical trial showed it was not effective and potentially harmful in a bronchiectasis population.⁴⁷ We note that there is an active trial exploring the use of nebulised RhDNase in ventilated ARF patients. This trial aims to recruit 500 patients to explore the use of to reduce the incidence of ARDS.⁴⁸ Expected to complete in 2021, it will likely provide evidence to guide the use of RhDNase.

Eight trials in this review explored the effectiveness of intravenous NAC and a subgroup analysis highlighted that there was no benefit in mortality or duration of ventilation, however, there was a reduction in ICU stay. Our analysis of NEBULAE,²⁶ with nebulised NAC, showed no improvement with outcomes with some evidence suggesting it may be associated with more adverse events. Our review supports the conclusions of a previous systematic review highlighting the need for more data to support use of NAC in the critically ill.⁴⁹ Another review focusing on NAC use in ARDS also found a reduction of ICU stay based on three trials.⁵⁰ However, they did not use the full core outcome set²¹ for ventilated trials or search for HFNO trials. There is a small ongoing trial expected to be complete later this year, exploring nebulised NAC in 52 ARDS patients.⁵¹

The second most common mucoactive explored in this review was nebulised heparin, showing no improvement in clinical outcomes with the exception of one trial⁴⁰ showing an improvement in ventilator free days. One trial that explored ambroxol showed improvements in duration of ventilation and reduced ICU and hospital stay. However, we acknowledge that ambroxol is not available in the UK. One trial²⁹ exploring the efficacy of HTS showed significant reductions in mortality, duration of mechanical ventilation and ICU stay but this trial was small and methodolog-ically flawed.

Our recent survey of ICU unit level practice¹⁷ and a point prevalence survey⁵² exploring the use of mucoactive agents in ARF, showed HTS and carbocisteine are the most commonly used. Alongside this review, it provides justification for a clinical trial to explore the effectiveness of these mucoactive agents in ARF. These interventions could have adverse effects, and the resource use in terms of staff time to administer therapy, particularly those that are nebulised, may be significant. Conversely if any of these mucoactives have a positive significant impact on clinical outcomes there is also potential for savings such as reduced costs associated with shortened critical care and hospital stay. Also, these therapies are individually inexpensive, and a lack of robust evidence to support their use in practice may not deter some clinicians from continuing to prescribe them regardless of effectiveness. Nonetheless, as they are used in large numbers of critically ill patients, the overall scaled cost might be substantial.

The strength of our review is that it followed prespecified methods using a published protocol (PROSPERO) with duplicate and independent screening and data extraction. We also obtained a subgroup of data from one large trial to strengthen the metaanalysis providing a more accurate estimate of effect and used a full core outcome set²¹ with a five member panel grading the quality of evidence for each outcome. The major limitations of the results are the relatively small number and large heterogeneity of included trials, the low quality of evidence, and lack of relevant reported outcomes and associated data. Not all trials reported fully on adverse events which leaves important questions surrounding the safety and tolerability of mucoactive agents.

Conclusion

In conclusion, the evidence in this review suggests that use of mucoactive agents does not improve most clinical outcomes in ventilated patients with ARF. The findings do not support the current widespread clinical practice of various mucoactive agents in mechanically ventilated patients with ARF. However, there was considerable heterogeneity in included trials and the certainty of this evidence is low. Therefore, until further evidence is available, mucoactive agent use should be considered with caution in this population. This systematic review justifies investment in large, high-quality randomised controlled trials to explore the use of commonly used mucoactive agents, where evidence does not already exist (eg, carbocisteine) or is not adequate (eg, HTS), to inform practice. Such trials should include appropriate outcomes from the core outcome set for ventilated trials²¹ and report fully on adverse events.

Author affiliations

¹Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK

²Centre for Health and Rehabilitation Technologies, Institute of Nursing and Health Research, Ulster University, Newtownabbey, UK

³Department of Physiotherapy, The University of Melbourne, Melbourne, Victoria, Australia

 $^4 \mathrm{Lane}$ Fox Respiratory Unit, Guy's and Saint Thomas' NHS Foundation Trust, London, UK

⁵Oxford Critical Care, Oxford University Hospitals NHS Foundation Trust, Oxford, UK ⁶Bristol Royal Infirmary, University Hospitals Bristol NHS Foundation Trust, Bristol, UK ⁷University of Amsterdam, Academic Medical Center Department of Intensive Care Medicine, Amsterdam, Noord-Holland, Netherlands

⁸Mahidol University, Mahidol Oxford Tropical Medicine Research Unit, Bangkok, Thailand

⁹Nuffield Department of Medicine, Oxford University, Oxford, UK

¹⁰Division of Infection, Immunity and Respiratory Medicine, NIHR Manchester Biomedical Research Centre, The University of Manchester, Manchester, UK

Acknowledgements We would like to thank Rebecca Lancaster from Queen's University Belfast for help with the translation and screening of German language papers. We also thank the NEBULAE investigators for providing subgroup data for their trial that was funded by a grant from The Netherlands Organisation for Health Research and Development (ZonMW). We would also like to acknowledge the Professor John Glover Award for support. Lastly we acknowledge previous publication of preliminary data via conference posters in abstract books (Anand R et al. Should mucoactives be used in acute respiratory failure in the critically ill? Results from a systematic review. 2019; Anand R et al. Should mucoactives be used in acute respiratory failure in the critically ill: preliminary results from a systematic review? 2018).

Contributors All authors fulfilled ICMJE guidelines for authorship criteria. RA, DM, JB, BB, CY, BO and BC contributed to the conception, data collection, data analysis, drafting the article and critical revisions. MB, MS and JW contributed to conception and provided critical revisions to the article. DvM, FP and MJS contributed to provisional data collection and critical revisions. PD provided critical revisions to the article.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests JB, DM, BO and RA are investigators in an NIHR HTA funded trial of mucoactives in bronchiectasis.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as online supplementary information. Any additional details are available on reasonable request.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially,

and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD

Rohan Anand http://orcid.org/0000-0002-1957-5336

REFERENCES

- Prescott HC, Sjoding MW, Langa KM, et al. Late mortality after acute hypoxic respiratory failure. *Thorax* 2018;73:618–25.
- , Ranieri VM, Rubenfeld GD, et al, ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin definition. JAMA 2012;307:2526–33.
- 3 Bellani G, Laffey JG, Pham T, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA 2016;315:788–800.
- 4 Narendra DK, Hess DR, Sessler CN, et al. Update in management of severe hypoxemic respiratory failure. Chest 2017;152:867–79.
- 5 Harrison D. Number of mechanically ventilated patients during 2012 The Intensive Care National Audit & Research Centre (ICNARC), 2014.
- 6 Konrad F, Schreiber T, Brecht-Kraus D, et al. Mucociliary transport in ICU patients. Chest 1994;105:237–41.
- 7 Magazine R, Rao S, Chogtu B. Prescribing patterns of drugs in acute respiratory distress syndrome (ARDS): an observational study. J Clin Diagn Res 2015;9:FC01–4.
- 8 Mahmood NA, Chaudry FA, Azam H, et al. Frequency of hypoxic events in patients on a mechanical ventilator. Int J Crit Illn Inj Sci 2013;3:124–9.
- 9 Balsamo R, Lanata L, Egan CG. Mucoactive drugs. *Eur Respir Rev* 2010;19:127–33.
- 10 Elkins MR, Bye PTP. Mechanisms and applications of hypertonic saline. *J R Soc Med* 2011;104 Suppl 1:2–5.
- NICE Guidance 2018. Available: https://www.nice.org.uk/guidance [Accessed 20 Mar 2018].
- 12 Davidson AC, Banham S, Elliott M, et al. BTS/ICS guideline for the ventilatory management of acute hypercapnic respiratory failure in adults. *Thorax* 2016;71 Suppl 2:ii–35.
- 13 The Faculty of Intensive Care Medicine. *Guidelines for the provision of intensive care services*. 2nd Edn. The Faculty of Intensive Care Medicine, 2019.
- 14 Ehrmann S, Roche-Campo F, Sferrazza Papa GF, et al. Aerosol therapy during mechanical ventilation: an international survey. *Intensive Care Med* 2013;39:1048–56.
- 15 Grivans C, Lindgren S, Aneman A, et al. A Scandinavian survey of drug administration through inhalation, suctioning and recruitment maneuvers in mechanically ventilated patients. Acta Anaesthesiol Scand 2009;53:710–6.
- 16 Ehrmann S, Roche-Campo F, Bodet-Contentin L, et al. Aerosol therapy in intensive and intermediate care units: prospective observation of 2808 critically ill patients. Intensive Care Med 2016;42:192–201.
- 17 Borthwick M, McAuley D, Warburton J, et al. Mucoactive agent use in adult UK Critical Care Units: a survey of health care professionals' perception, pharmacists' description of practice, and point prevalence of mucoactive use in invasively mechanically ventilated patients. *PeerJ* 2020;8:e8828.
- 18 Millette BH, Athanassoglou V, Patel A. High flow nasal oxygen therapy in adult anaesthesia. *Trends in Anaesthesia and Critical Care* 2018;18:29–33.
- 19 Icard BL, Rubio E. The role of mucoactive agents in the mechanically ventilated patient: a review of the literature. *Expert Rev Respir Med* 2017;11:807–14.
- 20 Sadowska AM. N-Acetylcysteine mucolysis in the management of chronic obstructive pulmonary disease. *Ther Adv Respir Dis* 2012;6:127–35.
- 21 Blackwood B, Ringrow S, Clarke M, *et al*. A core outcome set for critical care ventilation trials. *Crit Care Med* 2019;47:1324–31.
- 22 Higgins JPT, Altman DG, Gøtzsche PC, *et al*. The Cochrane collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011;343:d5928.
- 23 Roth D, Heidinger B, Havel C, et al. Different mortality time points in critical care trials: current practice and influence on effect estimates in meta-analyses. Crit Care Med 2016;44:e737–41.
- 24 Higgins JPT, Thompson SG, Deeks JJ, *et al*. Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557–60.
- 25 Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014;14:135.
- 26 van Meenen DMP, van der Hoeven SM, Binnekade JM, et al. Effect of on-demand vs routine nebulization of acetylcysteine with salbutamol on Ventilator-Free days in intensive care unit patients receiving invasive ventilation: a randomized clinical trial. JAMA 2018;319:993–1001.

- 27 Deeks JJ, Higgins JP, Altman DG, Cochrane Statistical Methods Group. Analysing data and undertaking meta-analyses. In: *Cochrane Handbook for systematic reviews of interventions*., 2019: 23, 241–84.
- 28 Balshem H, Helfand M, Schünemann HJ, et al. Grade guidelines: 3. rating the quality of evidence. J Clin Epidemiol 2011;64:401–6.
- 29 Dahruog AH, Zaytoun TM, Abdella HM. Role of hypertonic saline nebulization therapy in patients with early acute respiratory distress syndrome. *Intensive Care Med Exp* 2017;5:74–84.
- 30 Masoompour SM, Anushiravani A, Tafaroj Norouz A. Evaluation of the effect of nebulized N-acetylcysteine on respiratory secretions in mechanically ventilated patients: randomized clinical trial. *Iran J Med Sci* 2015;40:309–15.
- 31 Domenighetti G, Suter PM, Schaller MD, et al. Treatment with N-acetylcysteine during acute respiratory distress syndrome: a randomized, double-blind, placebo-controlled clinical study. J Crit Care 1997;12:177–82.
- 32 Suter PM, Domenighetti G, Schaller MD, et al. N-Acetylcysteine enhances recovery from acute lung injury in man. A randomized, double-blind, placebo-controlled clinical study. Chest 1994;105:190–4.
- 33 Bernard GR, Wheeler AP, Arons MM, et al. A trial of antioxidants N-acetylcysteine and Procysteine in ARDS. Chest 1997;112:164–72.
- 34 Yong-Jun L, Juan C, Bin O, et al. Effect of high dose ambroxol on the extra-vascular lung water and oxygenation of patients with extra-pulmonary acute respiratory distress syndrome. Intensive Care Med 2014;40:S233.
- 35 Jepsen S, Herlevsen P, Knudsen P, et al. Antioxidant treatment with N-acetylcysteine during adult respiratory distress syndrome: a prospective, randomized, placebocontrolled study. Crit Care Med 1992;20:918–23.
- 36 Ortolani O, Conti A, De Gaudio AR, et al. Protective effects of N-acetylcysteine and rutin on the lipid peroxidation of the lung epithelium during the adult respiratory distress syndrome. Shock 2000;13:14–18.
- 37 Moradi M, Mojtahedzadeh M, Mandegari A, et al. The role of glutathione-Stransferase polymorphisms on clinical outcome of ALI/ARDS patient treated with N-acetylcysteine. Respir Med 2009;103:434–41.
- 38 Bandeshe H, Boots R, Dulhunty J, et al. Is inhaled prophylactic heparin useful for prevention and management of pneumonia in ventilated ICU patients?: the IPHIVAP Investigators of the Australian and New Zealand intensive care Society clinical Trials Group. J Crit Care 2016;34:95–102.
- 39 Saleh M, Omar E. Does nebulized heparin have value in acute respiratory distress syndrome patients in the setting of polytrauma? *Egypt J Bronchol* 2017;11:332–5.
- 40 Dixon B, Schultz MJ, Smith R, et al. Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trial. Crit Care 2010;14:R180.
- 41 ClinicalTrials.gov. N-Acetyl-Cysteine in early acute respiratory distress syndrome. Available: https://clinicaltrials.gov/ct2/show/NCT03346681 [Accessed 12 Jun 2018].
- 42 ClinicalTrials.gov. Inhaled dornase alpha to reduce respiratory failure after severe trauma. Available: https://clinicaltrials.gov/ct2/show/NCT03368092
- 43 Sathe NA, Krishnaswami S, Andrews J, et al. Pharmacologic agents that promote airway clearance in hospitalized subjects: a systematic review. *Respir Care* 2015;60:1061–70.
- 44 Strickland SL, Rubin BK, Haas CF, et al. AARC clinical practice guideline: effectiveness of pharmacologic airway clearance therapies in hospitalized patients. *Respir Care* 2015;60:1071–7.
- 45 Zheng J-P, Kang J, Huang S-G, *et al*. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (peace study): a randomised placebo-controlled study. *Lancet* 2008;371:2013–8.
- 46 Yang C, Chilvers M, Montgomery M, et al. Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev 2016;4:CD001127.
- 47 O'Donnell AE, Barker AF, Ilowite JS, *et al*. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. *Chest* 1998;113:1329–34.
- 48 ClinicalTrials.gov. Inhaled dornase alpha to reduce respiratory failure after severe trauma, 2017. Available: https://clinicaltrials.gov/ct2/show/NCT03368092 [Accessed 8 Mar 2019].
- 49 Tarrant BJ, Maitre CL, Romero L, et al. Mucoactive agents for adults with acute lung conditions: a systematic review. *Heart Lung* 2019;48:141–7.
- 50 Lu X, Ma Y, He J, et al. N-Acetylcysteine for adults with acute respiratory distress syndrome: a meta-analysis of randomized controlled trials. *Hong Kong Journal of Emergency Medicine* 2019;26:288–98.
- 51 ClinicalTrials.gov. N-Acetyl-Cysteine in early acute respiratory distress syndrome, 2017. Available: https://clinicaltrials.gov/ct2/show/NCT03346681 [Accessed 8 Mar 2019].
- 52 Borthwick M, Shyamsundar M, Warburton J. Mucoactive agents in acute respiratory failure: point prevalence survey of UK adult critical care. Mucoactive agents in acute respiratory failure: point prevalence survey of UK adult critical care, Birmingham. Forthcoming poster presentation. Intensive Care Society, 2019.

Thorax: first published as 10.1136/thoraxjnl-2019-214355 on 8 June 2020. Downloaded from http://thorax.bmj.com/ on June 6, 2025 at Department GEZ-LTA Erasmushogeschool Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.